Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for INVO Fertility (IVF) over the last 17 years, with Q3 2025 value amounting to $400000.0.

  • INVO Fertility's Cash & Equivalents fell 2000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of $741396.0 for FY2024, which is 21898.43% up from last year.
  • As of Q3 2025, INVO Fertility's Cash & Equivalents stood at $400000.0, which was down 2000.0% from $549181.0 recorded in Q2 2025.
  • In the past 5 years, INVO Fertility's Cash & Equivalents registered a high of $8.4 million during Q1 2021, and its lowest value of $90135.0 during Q4 2022.
  • In the last 5 years, INVO Fertility's Cash & Equivalents had a median value of $840407.0 in 2025 and averaged $2.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 230663.89% in 2021, then plummeted by 9841.45% in 2022.
  • INVO Fertility's Cash & Equivalents (Quarter) stood at $5.7 million in 2021, then tumbled by 98.41% to $90135.0 in 2022, then soared by 157.86% to $232424.0 in 2023, then surged by 218.98% to $741396.0 in 2024, then crashed by 46.05% to $400000.0 in 2025.
  • Its Cash & Equivalents stands at $400000.0 for Q3 2025, versus $549181.0 for Q2 2025 and $840407.0 for Q1 2025.